These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11349879)

  • 1. Thalidomide as an anti-angiogenic agent in relapsed gliomas.
    Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M
    J Neurooncol; 2001 Jan; 51(1):41-5. PubMed ID: 11349879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
    Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
    J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.
    Ruiz J; Case D; Enevold G; Rosdhal R; Tatter SB; Ellis TL; McQuellon RP; McMullen KP; Stieber VW; Shaw EG; Lesser GJ
    J Neurooncol; 2012 Feb; 106(3):611-7. PubMed ID: 21870118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
    Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB
    J Clin Oncol; 2003 Jun; 21(12):2299-304. PubMed ID: 12805330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
    Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
    Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.
    Turner CD; Chi S; Marcus KJ; MacDonald T; Packer RJ; Poussaint TY; Vajapeyam S; Ullrich N; Goumnerova LC; Scott RM; Briody C; Chordas C; Zimmerman MA; Kieran MW
    J Neurooncol; 2007 Mar; 82(1):95-101. PubMed ID: 17031553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reirradiation and lomustine in patients with relapsed high-grade gliomas.
    Arcicasa M; Roncadin M; Bidoli E; Dedkov A; Gigante M; Trovò MG
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):789-93. PubMed ID: 10098434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
    Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
    J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
    Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
    Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide as second-line chemotherapy for relapsed gliomas.
    Trent S; Kong A; Short SC; Traish D; Ashley S; Dowe A; Hines F; Brada M
    J Neurooncol; 2002 May; 57(3):247-51. PubMed ID: 12125988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
    Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G
    Oncol Rep; 2004 Jan; 11(1):93-5. PubMed ID: 14654909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
    McMeekin DS; Sill MW; Darcy KM; Abulafia O; Hanjani P; Pearl ML; Rubin SC; Rose PG; Small L; Benbrook DM
    Gynecol Oncol; 2012 Nov; 127(2):356-61. PubMed ID: 22796461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
    Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
    Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
    Vestermark LW; Larsen S; Lindeløv B; Bastholt L
    Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
    Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.